Pfizer Stock Price, News & Analysis

Pfizer and BioNTech announced that the FDA granted Emergency Use Authorization (EUA) for a 10-µg booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children aged 5 to 11. The CDC's recommendation is pending before shipping. This booster aims to enhance protection as Omicron subvariants dominate U.S. cases. A clinical trial is underway for younger children. The companies have also applied for regulatory approvals in Europe and plan global submissions. Eligible residents will receive vaccines for free under U.S. government provisions.

Pfizer (NYSE: PFE) has successfully completed the acquisition of Global Blood Therapeutics (GBT) for $68.50 per share, totaling approximately $5.4 billion. This strategic move enhances Pfizer's commitment to addressing the needs of the sickle cell disease (SCD) community, with GBT's portfolio including the first-in-class drug Oxbryta® (voxelotor). Pfizer aims to innovate and expedite treatments for SCD, which affects millions globally, particularly among underserved populations. GBT's assets also include promising investigational therapies, with FDA designations in place.

Pfizer (NYSE: PFE) announced positive results from its Phase 3 TALAPRO-2 study of TALZENNA (talazoparib) combined with XTANDI (enzalutamide) for men with metastatic castration-resistant prostate cancer (mCRPC), achieving the primary endpoint of radiographic progression-free survival (rPFS) with a hazard ratio of 0.696. Consistent efficacy was noted irrespective of homologous recombination repair gene mutations. While a trend towards improved overall survival was observed, it needs further analysis. Safety profiles were generally consistent with known data, paving the way for potential regulatory discussions.

Pfizer has completed its acquisition of Biohaven Pharmaceutical for $11.6 billion, paying $148.50 per share. This acquisition adds the innovative migraine therapy NURTEC® ODT and a portfolio of CGRP receptor antagonists, including rimegepant and zavegepant, to Pfizer's pipeline. These drugs aim to serve over 1 billion migraine patients globally. The merger enhances Pfizer's Internal Medicine portfolio with strong growth potential through 2030 and beyond. Biohaven became a wholly-owned subsidiary, while Biohaven Ltd. retained non-CGRP assets and will continue trading under the ticker BHVN.

Pfizer (PFE) and BioNTech (BNTX) announced the submission of a request to the FDA for Emergency Use Authorization of a 10-µg booster dose of their bivalent COVID-19 vaccine targeting the Omicron BA.4/BA.5 variant for children aged 5-11. This request is backed by safety and immunogenicity data. Additionally, a Phase 1/2/3 study has been initiated to evaluate the vaccine's safety and immune response among children aged 6 months to 11 years. The companies also plan to submit a marketing authorization application to the EMA for the same age group.

Pfizer Inc. (NYSE: PFE) has declared a $0.40 cash dividend for Q4 2022, marking the 336th consecutive quarterly dividend payment. The dividend will be payable on December 5, 2022, to shareholders on record as of November 4, 2022. This announcement highlights the company's ongoing commitment to return value to its shareholders.

Pfizer (NYSE: PFE) has announced an agreement to supply up to six million treatment courses of its COVID-19 oral treatment, PAXLOVID™, to the Global Fund for low-and-middle-income countries. These treatment courses will be available for procurement in 132 eligible countries beginning in 2022, pending regulatory approval. The agreement is part of Pfizer's strategy for equitable access to COVID-19 treatments. Additionally, Pfizer has established tiered pricing for different income classifications and signed prior agreements with UNICEF and the Medicines Patent Pool to enhance global access.

Pfizer Inc. (NYSE: PFE) is hosting a conference call for investors on November 1, 2022, at 10 a.m. EDT to discuss its Third Quarter 2022 Performance Report. The call will provide insights into the company's financial results and future strategies. Interested participants can join via webcast or by dialing specific numbers for different regions. Details for accessing the Performance Report and registration can be found on Pfizer's investor website, with a transcript available within 24 hours post-call.

Pfizer announced positive results from its pivotal Phase 3 study (NCT04546425) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC), targeting invasive pneumococcal disease in infants. The vaccine showed a favorable safety profile and robust immune responses, meeting non-inferiority criteria for 19 of 20 serotypes after the third dose. Pfizer intends to file for regulatory approval in the EU in the upcoming months. This vaccine, if approved, would provide comprehensive protection against pneumococcal disease, marking a significant milestone in pediatric vaccination.